Beigene Ltd (NASDAQ:BGNE) has been assigned an average recommendation of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $86.25.
A number of research analysts have recently issued reports on the company. Maxim Group set a $120.00 price target on Beigene and gave the company a “buy” rating in a report on Monday, January 22nd. ValuEngine raised Beigene from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research raised Beigene from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th.
Beigene (NASDAQ BGNE) opened at $136.64 on Tuesday. The stock has a market capitalization of $7,213.63, a price-to-earnings ratio of -105.11 and a beta of 0.61. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20. Beigene has a 1-year low of $34.36 and a 1-year high of $142.00.
Hedge funds have recently bought and sold shares of the business. Canada Pension Plan Investment Board purchased a new stake in Beigene in the third quarter worth about $62,076,000. Janus Henderson Group PLC purchased a new stake in Beigene in the third quarter worth about $33,744,000. Artal Group S.A. increased its position in Beigene by 33.3% in the fourth quarter. Artal Group S.A. now owns 300,000 shares of the company’s stock worth $29,316,000 after buying an additional 75,000 shares in the last quarter. California Public Employees Retirement System purchased a new stake in Beigene in the third quarter worth about $4,912,000. Finally, Horseman Capital Management Ltd purchased a new stake in Beigene in the fourth quarter worth about $4,515,000. 49.35% of the stock is currently owned by institutional investors.
Beigene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.